Remedium Research Pre-Filled Pen No Reconstitution

Lab report

Buy Retatrutide 30mg Pen in Dubai

Triple-receptor agonist tested in phase 3 trials

Janoshik tested 99.262% HPLC Batch RETP002 Exact-format report

AED 1,600 / pen

In stock 30mg per pen Pre-filled pen device, 3mL cartridge

Quantity
30mg per pen
Format
Pre-filled pen device, 3mL cartridge
Purity
≥99% (HPLC verified by Janoshik)

JanoshikBatch RETP002

99.262% HPLC Exact-format report

This report does not confirm the current shipping lot.

Choose your bundle

Free UAE delivery on this order

  1. OrderBefore 4 PM for Dubai
  2. PackedCold-chain, 2–8°C
  3. DeliveredSame day in Dubai, next day elsewhere in the UAE

Order before 4 PM for same-day Dubai delivery.

UAE delivery: AED 50 below AED 1,000; free from AED 1,000

Pay byCash on delivery (Dubai)Card payment linkUSDT

Sold by
Remy Research
Brand
Remedium Research
Manufacturer
Remedium Research
Tested by
Janoshik Analytical — published report
Batch report
View batch RETP002 COA · Exact-format report: Reta 30mg Pen, analysed 4 Nov 2025. This report does not confirm the current shipping lot.
  • 99%+ purityJanoshik · Exact-format report
  • Same-day DubaiOrder before 4 PM for same-day delivery
  • FormatPre-filled pen device, 3mL cartridge
  • Cold-chain packed2–8°C

Remedium Retatrutide 30mg Pen: What the Research Shows

  • 25.0% average weight loss in 80 weeks
  • 1.94% average HbA1c drop in 40 weeks
  • 82.4% average liver-fat reduction in 24 weeks

Published study results for the compound, not results from this product. For research use only.

The Remedium Retatrutide 30mg pen is a pre-filled FlexiPen device containing 30mg of Retatrutide in a 3mL cartridge, with Janoshik batch verification showing 99.262% HPLC purity for RETP002 and same-day delivery available in Dubai from Remy Research. Built for laboratory scientists and professional researchers in the UAE and GCC conducting in-vitro peptide research, it provides a research-grade, ready-to-use format with no reconstitution, no vials, and no syringes.

Buy the Remedium Retatrutide 30mg pen in Dubai from Remy Research. Pre-filled pen; the published Janoshik report for batch RETP002 records 99.262% HPLC purity. No reconstitution, no vials, no syringes. Click-dose accuracy with every injection. Same-day Dubai delivery available.

This page details the pen's specifications, HPLC purity verification, cold-chain delivery and storage requirements, included contents, and the wider Retatrutide research context, including its triple receptor agonist mechanism and how it compares with related peptides used in metabolic and biochemical studies. For labs needing traceable COA-backed material, fast local fulfilment, and high-purity Retatrutide for obesity, glycaemic, and liver-fat research, the pen format offers verified, ready-to-use supply for research use only, with the batch report linked on this page.

Compound: Retatrutide CAS Number: 2381089-83-2 Quantity: 30mg per pen Format: Pre-filled pen device, 3mL cartridge Purity: ≥99% (HPLC verified by Janoshik) Storage: +2 to +8°C; maintain cold chain; no freezing; protect from light
≥99% Purity
Janoshik Verified
Same-Day Delivery
Dubai
Pre-Filled Pen
No Reconstitution
Cold-Chain Shipped
+2 to +8°C
What Is Included

COAs are published for every batch supplied and verify identity and purity using methods such as HPLC and mass spectrometry, with checks for endotoxins and heavy metals. Each pen includes a batch-matched Certificate of Analysis for verification.

  • 1 × 30mg pre-filled pen
  • 20 × sterile pen needles (31G, 5mm)
  • 1 × insulated shipper; the pen ships under cold-chain conditions from facility to delivery and should be refrigerated on receipt
  • 1 × product insert directing researchers to the product label and batch documentation for storage, expiry, handling instructions, and batch verification
  • Related resources for batch-specific research reference only; not for human consumption

Other formats of Retatrutide

Published batch records

BatchPurityReportTaskVerify keyReport link
RETP002 99.262% HPLC Purity Certificate 86428 97SPA7G1BJUL View report

RETP002 evidence record

Also available

Ships from Dubai

All Peptides

What Is Retatrutide? Insights from Clinical Trials

Retatrutide (LY-3437943) is an investigational triple receptor agonist peptide that activates three metabolic receptors: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This tri-receptor mechanism is the basis for the compound being studied as one of the most potent investigational research compounds in this class.

In the 2023 Phase 2 trial published in the New England Journal of Medicine, the 12-mg retatrutide group had a least-squares mean body-weight change of −24.2% at 48 weeks, compared with −2.1% with placebo. In the completed Phase 3 TRIUMPH-1 trial, Lilly’s May 2026 topline results showed average weight changes at 80 weeks of −19.0% with 4mg, −25.9% with 9mg, and −28.3% with 12mg, compared with −2.2% with placebo. In a prespecified 104-week extension among participants with baseline BMI ≥35, the 12-mg group reached an average −30.3% weight change. These are Lilly’s May 2026 topline figures (efficacy estimand). The full TRIUMPH-1 results were published in The New England Journal of Medicine on 29 September 2026: in the primary treatment-regimen analysis, mean weight change at 80 weeks was −17.6% (4mg), −23.7% (9mg) and −25.0% (12mg), compared with −3.9% with placebo. TRIUMPH-2, in adults with obesity and type 2 diabetes, was published in The Lancet the same day. Retatrutide remains investigational and is not approved anywhere; Lilly plans to submit retatrutide for US approval in Q1 2027.

Unlike semaglutide and tirzepatide, retatrutide also activates the glucagon receptor, which is studied for effects on energy expenditure and liver fat. GLP-1/glucagon dual agonists such as survodutide and mazdutide share that glucagon component.

In published research, including a 2023 Phase 2 study in the New England Journal, retatrutide was evaluated as a once-weekly subcutaneous injection, with administration sites in study protocols including the abdomen, thigh, and upper arm, and the target dose was reached gradually over time.

That Phase 2 trial reported a 24.2% reduction in body weight and an average 19.6 cm drop in waist circumference versus the placebo group. Separate TRIUMPH-1 data reported 28.3% weight loss at 12 mg during treatment.

Trial designs typically adjusted the current dose gradually to limit gastrointestinal events, and higher doses were associated with more nausea, diarrhea, vomiting, and decreased appetite. Dysesthesia occurred in 12.5% of participants at the highest dose, and urinary tract infections were more common in retatrutide arms.

In type 2 diabetes studies, clinical evaluations also found meaningful reductions in HbA1c and fasting plasma glucose, including among participants with obesity or a weight-related condition.

Long term effects remain under study, especially as Phase 3 programs continue gradual escalation toward a planned dose, and this investigational agent is not established for personal treatment; serious risks may include pancreatitis and gallbladder problems, with added caution for anyone with prior pancreatitis or major gastrointestinal issues, so general medical decisions should be discussed with a healthcare provider.

Why Buy Retatrutide from Remy Research?

Pre-filled pen format.

Most suppliers sell Retatrutide as lyophilized powder in vials. That means you need bacteriostatic water, syringes, and the knowledge to reconstitute correctly. One mistake and you compromise the product or the dose. Our 30mg FlexiPen is pre-filled, pre-mixed, and ready to use. Dial your dose, click, done.

≥99% purity, Janoshik verified.

Batch RETP002 has one published report from Janoshik Analytical, an independent third-party laboratory (task 86428, analysed 4 November 2025): HPLC purity 99.262% and a measured concentration of 12.09 mg/mL. The test was commissioned by the manufacturer, Remedium Research. Verified data you can check yourself.

Research-grade packaging.

Every order ships with the pen device, 20 sterile pen needles (31G, 5mm), and a product information insert with full dosing guidance. Outer carton, sealed needle box, cold-chain packaging.

Same-day Dubai delivery.

Dubai orders placed before 4 PM are delivered the same day. Outside Dubai, order before 12 PM (noon) for next-day delivery. Orders placed on Saturday will be delivered on Monday, and Sunday delivery is not available outside Dubai. Delivery costs AED 50 below AED 1,000 and is free from AED 1,000. Cold-chain packed at 2–8°C to your door.

Stabilized and pH-balanced formula.

The FlexiPen is supplied as a ready-to-use, pH-balanced solution rather than as a powder for reconstitution.

Manufactured by Remedium Research.

The Retatrutide 30mg FlexiPen is manufactured by Remedium Research and sold in the UAE by Remy Research.

Retatrutide chemistry & specifications

Identity

GIP, GLP-1 and glucagon receptor agonist peptide

Retatrutide (LY3437943)

Also known asReta, LY3437943, LY-3437943

CAS
2381089-83-2

Molecule

Formula
C221H342N46O68
Molecular weight
4,731 g/mol Registry value for the peptide without counter-ions; not measured for this batch.
Sequence
39-residue backbone with a lipidated side chain · How the amino acids are counted

This product

Manufacturer
Remedium Research
Quantity
30mg per pen
Format
Pre-filled FlexiPen, 3mL cartridge
Purity
≥99% (HPLC verified by Janoshik)
Testing
HPLC purity and concentration (Janoshik, batch RETP002)
Storage
+2 to +8°C. Maintain cold chain. Do not freeze. Protect from light.

Batch documentation

Janoshik Analytical — published report

Batch
RETP002
HPLC purity
99.262%
Laboratory
Janoshik Analytical
Analysed
4 Nov 2025
Reports
1 published
Sample tested
Reta 30mg Pen
Applies to
Remedium Research 30mg Retatrutide FlexiPen

Reference data for laboratory checks. Registry values describe the compound, not measurements of this batch. For research use only.

How Retatrutide Works — Triple Receptor Mechanism and Glucagon Receptors

Retatrutide activates three receptor pathways simultaneously: semaglutide acts on one of them (GLP-1), tirzepatide on two (GLP-1 and GIP), and GLP-1/glucagon dual agonists such as survodutide on two (GLP-1 and glucagon).

GLP-1 (glucagon-like peptide 1) receptor

Promotes satiety signaling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. This is the same pathway targeted by semaglutide and by the GLP-1 component of tirzepatide.

GIP (glucose dependent insulinotropic polypeptide) receptor

Enhances insulin response after meals, has direct effects on adipose tissue, and works synergistically with GLP-1 to amplify metabolic signaling. This is the second pathway targeted by tirzepatide, making it a dual agonist. Retatrutide includes this plus a third target.

Glucagon receptor

Increases resting energy expenditure, promotes hepatic lipid oxidation, and mobilizes stored fat for fuel. This is the component that distinguishes Retatrutide from semaglutide and tirzepatide, which do not activate the glucagon receptor at all; GLP-1/glucagon dual agonists such as survodutide share it.

TRIUMPH-1, published in the New England Journal of Medicine, compared retatrutide with placebo; a head-to-head Phase 3 trial against tirzepatide (TRIUMPH-5) was still under way in October 2026.

Retatrutide vs Tirzepatide vs Semaglutide — Weight Management Research Comparison

PropertyRetatrutideTirzepatideSemaglutide
Receptor TargetsGLP-1 + GIP + GlucagonGLP-1 + GIPGLP-1 only
MechanismTriple receptor agonistDual receptor agonistSingle receptor agonist
Mean weight loss, highest dose (treatment-regimen)25.0% at 80 weeks (TRIUMPH-1)20.9% at 72 weeks (SURMOUNT-1)14.9% at 68 weeks (STEP 1)
Increases Energy ExpenditureYes (glucagon)NoNo
Promotes Direct Fat OxidationYes (glucagon)NoNo
Regulatory status (research literature)Investigational (Phase 3, TRIUMPH program)Approved for human useApproved for human use
Format (at Remy Research)30mg pre-filled FlexiPenN/AN/A

For research purposes only. Not for human consumption. Published reports correspond to the product and batch shown.

Plan clicks and pen duration

The Remedium 30mg FlexiPen holds 300 clicks of 0.1mg each, and the dial turns up to 60 clicks at a time. Pen Planner shows how many clicks an amount in mg takes and how long one pen lasts. Pen Clicks to mg turns a dial reading back into mg.

Frequently Asked Questions

Where can I buy the retatrutide 30mg pen in Dubai?

You can buy Retatrutide in Dubai from Remy Research. We offer the Remedium Research 30mg pre-filled FlexiPen; the published Janoshik report for batch RETP002 records 99.262% HPLC purity. Same-day Dubai delivery is available on orders placed before 4 PM.

What is the difference between Retatrutide pens and vials?

Most suppliers sell Retatrutide as lyophilized powder in vials that must be reconstituted with bacteriostatic water before use. This requires syringes, sterile technique, and introduces the risk of contamination or dosing errors. The Remedium Research FlexiPen is pre-filled and ready to inject with precise click-dose accuracy. No reconstitution, no syringes, no guesswork.

How much is the retatrutide 30mg pen in Dubai?

A single 30mg Retatrutide FlexiPen is AED 1,600. 2 pens are AED 1,200 per pen, and 5 pens are AED 800 per pen.

How should I store the Retatrutide pen?

Store between +2 and +8 degrees C (standard refrigerator temperature). Do not freeze. Protect from light. The pen ships in cold-chain insulated packaging and should be refrigerated immediately upon receipt.

What is Retatrutide?

Retatrutide (LY-3437943) is an investigational triple receptor agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. In the 2023 Phase 2 trial published in the New England Journal of Medicine, the 12-mg retatrutide group had a least-squares mean body-weight change of −24.2% at 48 weeks, compared with −2.1% with placebo. In the completed Phase 3 TRIUMPH-1 trial, Lilly’s May 2026 topline results showed average weight changes at 80 weeks of −19.0% with 4mg, −25.9% with 9mg, and −28.3% with 12mg, compared with −2.2% with placebo. In a prespecified 104-week extension among participants with baseline BMI ≥35, the 12-mg group reached an average −30.3% weight change. These are Lilly’s May 2026 topline figures (efficacy estimand). The full results were published on 29 September 2026: TRIUMPH-1 in The New England Journal of Medicine (mean weight change −25.0% with 12mg vs −3.9% with placebo at 80 weeks, treatment-regimen analysis) and TRIUMPH-2 in The Lancet. Retatrutide is investigational and not approved anywhere.

How does Retatrutide compare to tirzepatide and semaglutide?

Retatrutide is described in published research as targeting three receptors (GLP-1, GIP, glucagon), compared to two for tirzepatide (GLP-1, GIP) and one for semaglutide (GLP-1). Mean body-weight reductions at the highest dose in each Phase 3 trial’s primary (treatment-regimen) analysis: 25.0% for retatrutide at 80 weeks (TRIUMPH-1), 20.9% for tirzepatide at 72 weeks (SURMOUNT-1) and 14.9% for semaglutide at 68 weeks (STEP 1). The glucagon component is reported in the literature to act on energy expenditure and fat oxidation pathways that tirzepatide and semaglutide do not engage.

Who manufactures the Retatrutide pen sold by Remy Research?

The Retatrutide 30mg FlexiPen is manufactured by Remedium Research and sold by Remy Research. The published Janoshik report for batch RETP002 of this pen records 99.262% HPLC purity.

What are the chemical identifiers of Retatrutide?

Retatrutide (LY3437943) has CAS number 2381089-83-2, molecular formula C221H342N46O68, molecular weight 4,731 g/mol, PubChem CID 171390338. These are registry values for the compound, not measurements of a batch.

Is there a batch certificate of analysis (COA) for this pen?

Yes. Batch RETP002 was analysed by Janoshik Analytical on 4 Nov 2025. The sample tested was Reta 30mg Pen; it recorded 99.262% HPLC purity across 1 published report. Each certificate and its Janoshik verification link are on the batch page.

Can I buy a Retatrutide pen online for research in the UAE?

Yes. Remy Research sells the Remedium Research 30mg Retatrutide FlexiPen online at AED 1,600. It is supplied for laboratory research use only. Order through website checkout. Dubai orders placed before 4 PM arrive the same day. Other emirates get next-day delivery on orders placed before 12 PM (noon). The pen is cold-chain packed at 2 to 8°C.

Can I buy the Remedium Retatrutide 30mg pen for weight loss?

Not for that purpose. The Remedium Research Retatrutide 30mg FlexiPen is a pre-filled pen with a 3mL cartridge at AED 1,600, supplied for laboratory research only. Retatrutide is investigational and lacks FDA approval. No advice on personal use is given, and the trial figures describe the compound itself.

Does Remy Research sell a 10mg or 20mg Retatrutide pen?

This page is the Remedium Research 30mg FlexiPen, 30mg in a 3mL cartridge at AED 1,600. ProPeptide retatrutide pens come in 10mg, 20mg and 40mg. Vial options include a ProPeptide retatrutide vial and a ZPHC 20mg kit of five 4mg vials. All are supplied for laboratory research use only.

Is there a shop where I can buy the Remedium Retatrutide 30mg pen near me in Dubai?

The Remedium Research Retatrutide 30mg FlexiPen at AED 1,600 comes from an online-only shop, so there is no walk-in store or pickup point. Checkout happens on the website. Orders placed in Dubai before 4 PM arrive that same day. This FlexiPen has a 3mL cartridge and is supplied for laboratory research use only.

Is GLP-3 RT the same as retatrutide?

Yes. Some sellers list retatrutide (LY-3437943) as GLP-3 or GLP-3 RT. That is a nickname, not a separate compound or drug class: retatrutide acts on the GIP, GLP-1 and glucagon receptors, and there is no GLP-3 hormone. This pen contains retatrutide and is supplied for laboratory research use only.